Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Change in Account Payables: 2019-2025

Historic Change in Account Payables for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to $2.2 million.

  • Nurix Therapeutics' Change in Account Payables rose 103.93% to $2.2 million in Q3 2025 from the same period last year, while for Aug 2025 it was $3.9 million, marking a year-over-year increase of 72.82%. This contributed to the annual value of $5.2 million for FY2024, which is 222.74% up from last year.
  • As of Q3 2025, Nurix Therapeutics' Change in Account Payables stood at $2.2 million, which was up 183.35% from -$2.7 million recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Change in Account Payables registered a high of $7.6 million during Q4 2024, and its lowest value of -$3.2 million during Q1 2025.
  • For the 3-year period, Nurix Therapeutics' Change in Account Payables averaged around $288,000, with its median value being -$930,000 (2024).
  • Per our database at Business Quant, Nurix Therapeutics' Change in Account Payables spiked by 617.24% in 2023 and then slumped by 332.50% in 2024.
  • Quarterly analysis of 5 years shows Nurix Therapeutics' Change in Account Payables stood at $862,000 in 2021, then tumbled by 204.29% to -$899,000 in 2022, then soared by 617.24% to $4.7 million in 2023, then skyrocketed by 63.12% to $7.6 million in 2024, then skyrocketed by 103.93% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, -$2.7 million for Q2 2025, and -$3.2 million during Q1 2025.